论文部分内容阅读
作者采用Vigabatrin(VT)治疗耐药性局限性癫痫取得满意效果,着重报告5年随访结果。共55例患者,28例接受VT每天3.0g,27例接受VT每天1.5g,1例停药。全部患者的最终平均用量为每天3.07 g(1.5～5.0g),或45mg/kg(18～93 mg/kg)。患者既往均使用过1.97种抗癫痫药物。研究表明,用药前,本组病人的癫痫发作次数为每月12.3次,使用VT后,发作次数减少到每月3.3次,随访2年时,平均癫痫发作次数略有增加,但随访3年时,其发作次数又降到每月4次。28例患者完成了5年的随
The authors achieved satisfactory results with Vigabatrin (VT) for the treatment of drug-resistant, localized epilepsy, with a focus on reporting 5-year follow-up results. A total of 55 patients, 28 patients received VT 3.0g per day, 27 patients received VT 1.5g per day, 1 patient discontinued. The final average dose for all patients was 3.07 g (1.5-5.0 g), or 45 mg / kg (18-93 mg / kg) daily. The patient has used 1.97 kinds of antiepileptic drugs in the past. The study showed that before treatment, the number of seizures in this group of patients was 12.3 times per month. After VT was used, the number of seizures decreased to 3.3 times per month. At the follow-up of 2 years, the average number of seizures increased slightly, but at 3 years of follow-up , The number of attacks has dropped to 4 times per month. 28 patients completed 5 years of follow-up